112,476 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Deutsche Bank AG

Deutsche Bank AG acquired a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 112,476 shares of the company’s stock, valued at approximately $1,959,000. Deutsche Bank AG owned approximately 0.21% of Bicara Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Spire Wealth Management purchased a new stake in Bicara Therapeutics in the 4th quarter worth $31,000. BNP Paribas Financial Markets bought a new position in shares of Bicara Therapeutics in the fourth quarter worth about $32,000. Legal & General Group Plc purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $33,000. Summit Investment Advisors Inc. bought a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $35,000. Finally, Virtus ETF Advisers LLC bought a new position in Bicara Therapeutics in the fourth quarter worth approximately $69,000.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock opened at $9.27 on Friday. The business has a 50 day simple moving average of $12.91 and a 200-day simple moving average of $14.96. Bicara Therapeutics Inc. has a 12 month low of $7.80 and a 12 month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28). As a group, research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BCAX has been the topic of several analyst reports. Wall Street Zen lowered shares of Bicara Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Cantor Fitzgerald reissued an “overweight” rating and set a $13.01 price target on shares of Bicara Therapeutics in a report on Thursday, March 13th. Wells Fargo & Company raised shares of Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price target for the company in a report on Friday. Wedbush restated an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a report on Friday. Finally, HC Wainwright cut their target price on Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating for the company in a research note on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.86.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.